Carbapenem-based versus non-carbapenem therapy for hospital-acquired and ventilator-associated pneumonia in a resource-limited setting: a retrospective cohort study of clinical outcomes
Journal of Pharmacy & Pharmaceutical Sciences · 2026
DOI: 10.3389/jpps.2026.17336 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, 2026. Verfasst von Uroosa Kanwal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan. Hauptthemen laut MEDLINE: Pneumonia, Ventilator-Associated, Carbapenems, Anti-Bacterial Agents, Healthcare-Associated Pneumonia. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Pneumonieprophylaxe
Abstract (Originalsprache)
Background
Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are major causes of in-hospital mortality and antimicrobial resistance (AMR), particularly in low- and middle-income countries (LMICs). Carbapenems are commonly used due to their broad-spectrum activity; however, their efficacy in real-world clinical practices comparing carbapenem with non-carbapenem regimens in these settings is limited.
Objectives
To compare clinical outcomes between patients receiving carbapenem-based and non-carbapenem therapy for HAP and VAP at a tertiary care hospital in Pakistan.
Methods
This retrospective cohort study included 93 adult patients (HAP: n = 62, VAP: n = 31) over the period of 1 year. Demographics, comorbidities, microbial isolates, treatment regimen, and clinical outcomes were analyzed using descriptive statistics, chi-square tests, and risk ratio calculations with 95% confidence interval. Multivariable logistic regression was planned to adjust for confounders but was not feasible due to missing severity score and biomarker data.
Results
HAP was more common in females (63%), while VAP showed a male predominance (52%). The most common pathogens were Acinetobacter spp. (HAP: 11.3%; VAP: 19.4%) and Pseudomonas aeruginosa (HAP: 11.3%; VAP: 16.1%). The most prevalent comorbidity in HAP was diabetes mellitus (38.7%). Carbapenem-based therapy (meropenem) was used in 65.6% of cases and the most frequently prescribed non-carbapenem agents were piperacillin-tazobactam, ceftazidime, and colistin. No significant difference in mortality was observed between carbapenem and non-carbapenem therapy in HAP (31.6% vs. 29.2%; RR 1.08, 95% CI 0.50–2.36, p = 0.840) or VAP (65.2% vs. 50.0%; RR 1.30, 95% CI 0.61–2.77, p = 0.440). VAP was associated with significantly higher crude mortality than HAP (61.3% vs. 30.6%; p = 0.005). Crude mortality rates appeared highest among patients in the Acinetobacter baumannii group (70.4%) and Pseudomonas aeruginosa group (31.3%), though treatment group difference were not statistically significant.
Conclusion
In this single-center retrospective cohort, no statistically significant association between carbapenem-based therapy and all-cause in-hospital mortality was detected in HAP or VAP. Crude mortality appeared highest among patients with Acinetobacter and Pseudomonas isolates. However, wide confidence intervals, treatment-selection bias, and unadjusted analyses preclude definitive conclusions. These findings should be considered hypothesis-generating, requiring confirmation in adequately powered, larger prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan.
- Department of Pharmacy Practice, Faculty of Pharmacy, Salim Habib University, Karachi, Pakistan.
- Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Dow College of Pharmacy, Dow University of Health Sciences, Karachi, Pakistan.
- Department of Clinical Pharmacy, College of Pharmacy, Al-Farahidi University, Baghdad, Iraq.
- Department of Pediatrics, Liaquat National Hospital, Karachi, Pakistan.
- Department of Infectious Diseases, Dow University Hospital, Dow University of Health Sciences, Karachi, Pakistan.
Zitieren
APA
Kanwal, U., Muhammad, I. N., Zehra, A., Shah, S. S. A. M., Abro, F., Ansari, T., Rahim, N., Munawar, R., & Hussain, M. (2026). Carbapenem-based versus non-carbapenem therapy for hospital-acquired and ventilator-associated pneumonia in a resource-limited setting: a retrospective cohort study of clinical outcomes. Journal of Pharmacy & Pharmaceutical Sciences. https://doi.org/10.3389/jpps.2026.17336
Vancouver
Kanwal U, Muhammad IN, Zehra A, Shah SSAM, Abro F, Ansari T, et al. Carbapenem-based versus non-carbapenem therapy for hospital-acquired and ventilator-associated pneumonia in a resource-limited setting: a retrospective cohort study of clinical outcomes. Journal of Pharmacy & Pharmaceutical Sciences. 2026. doi:10.3389/jpps.2026.17336
BibTeX
@article{Kanwal2026,
author = {Kanwal, Uroosa and Muhammad, Iyad Naeem and Zehra, Ale and Shah, Syed Shaukat Ali Muttaqi and Abro, Falak and Ansari, Tehreem and Rahim, Najia and Munawar, Rabya and Hussain, Mujahid},
title = {Carbapenem-based versus non-carbapenem therapy for hospital-acquired and ventilator-associated pneumonia in a resource-limited setting: a retrospective cohort study of clinical outcomes},
journal = {Journal of Pharmacy & Pharmaceutical Sciences},
year = {2026},
doi = {10.3389/jpps.2026.17336}
}
EUVIMED